Your Health, We Care
The authoritative journal Kidney International has released the Quality of Life Measurement Study on HIF-PHI daprodustat (ASCEND-NHQ). Daprodustat monotherapy can significantly increase hemoglobin (Hb) levels in non dialysis CKD patients and improve fatigue symptoms in patients with mild to moderate anemia.
Kyowa Kirin launched the new anemia drug daprodustat tablets in the Japanese market in June 2020, further demonstrating the importance and application prospects of daprodustat in the international pharmaceutical market.
